Global Activated Partial Thromboplastin Time Test Market Projected to Surpass $601.2 Million, Growing at 6.8% CAGR from 2019 to 2026 [130-Pages] | Confirmed by Research Dive
The global activated partial thromboplastin time test market is projected to experience remarkable growth in the upcoming years. Rising advancements and improvements by market players in activated partial thromboplastin time tests is fueling the growth of the market. The point-of-care testing sub-segment and instruments sub-segment are estimated to lead the market. The Asia-Pacific market is projected to observe significant growth.
New York, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- A new report on the global activated partial thromboplastin time test market has been added by Research Dive to its repository. As per the report, the market is expected to garner $601.2 million by 2026, growing at a CAGR of 6.8% from 2019 to 2026. This report provides thorough insights into the present condition and future outlook of the global industry. The report is drafted by professional market analysts and assures to be a reliable source of data and detailed market insights for new players, investors, prevailing market players, stakeholders, shareholders, etc.
Factors Impacting the Activated Partial Thromboplastin Time Test market Growth:
Rising demand for activated partial thromboplastin time testing devices in medical organizations is fueling the growth of the global activated partial thromboplastin time test market. Furthermore, growing advancements and improvements by market players in activated partial thromboplastin time tests are projected to give rise to profitable opportunities for market growth during the forecast period. However, the high costs of test devices are anticipated to hinder market growth.
Access a PDF Sample Report of Activated Partial Thromboplastin Time Test market@ https://www.researchdive.com/download-sample/79
End of Season BIGGEST DISCOUNT EVER
End of Season Discount: Flat 20% OFF on Activated Partial Thromboplastin Time Test market
Purchase Option Available
Individual User (Single User) at $ 4560
Multi-User Access at $8700 TO $6960
Business User Access at $10700 TO $8560
(*Offer Limited Period Only)
The report segments the global activated partial thromboplastin time test market into product type, end-use, and region.
Instruments Sub-Segment to Experience Remarkable Growth
Among the product type segment, the instruments sub-segment is expected to experience significant growth with a CAGR of 7.2% during the forecast period. The growth of this sub-segment is mostly because of the growing focus of manufacturers on enhancing the future generations of instruments for medical diagnosis by improving productivity, precision, and overall performance at a minimal treatment cost.
Point-of-care Testing Sub-Segment to Observe Noteworthy Growth
Among the end-use segment, the point-of-care testing sub-segment of the activated partial thromboplastin time test market is projected to grow with a 7.7% CAGR during the estimated timeframe. This is mostly because of a rising number of point-of-care testing diagnosis centers worldwide.
Asia-Pacific Region to Witness Remarkable Growth
The report analyzes the global activated partial thromboplastin time test market across several regions such as Asia-Pacific, Europe, Asia Pacific, and LAMEA. Among these, the Asia-Pacific region market is expected to grow significantly and garner $143.1 million during the estimated timeframe. The growth of this region's market is mainly owing to the rising developments in the healthcare sector in the region.
Major Players in the Activated Partial Thromboplastin Time Test market:
The report lists some of the leading players functioning in the global activated partial thromboplastin time test market including
- Abbott
- Danaher
- bioMérieux, Inc.
- Bio-Rad Laboratories, Inc.
- Siemens Healthcare Private Limited
- Hoffmann-La Roche Ltd
- Takara Bio Inc.
- ThermoFisher
- Ortho Clinical Diagnostics
- HORIBA, Ltd.
- Beckman Coulter, Inc.
The report also offers several industry-top tactics and approaches such as top strategic moves & developments, product/service range, business performance, Porter five forces analysis, and SWOT analysis of the foremost players, functioning in the global industry. For instance, in December 2018, Sysmex, a company focused on offering health services with diagnostic solutions that alter the future of healthcare and contribute to healthier lives, launched Revohem FIX Chromogenic, a Blood Coagulation Factor IX measurement kit by using Chromogenic Assay, to help in the diagnoses and assistance of the treatment of Hemophilia B.
In Addition, the report has numerous points about the leading Business Manufactures, Like, SWOT analysis, Product Portfolio, Financial Status - Inquire to Get access for Detailed Top Companies Development Strategy Report
Related Article Links:
- All your questions about Activated Partial Thromboplastin answered
- The Activated Partial Thromboplastin Time test is essential to prevent the dangerous clots
Contact: Mr. Abhishek Paliwal Research Dive 30 Wall St. 8th Floor, New York NY 10005 (P) +91-(788)-802-9103 (India) +1-(917)-444-1262 (US) Toll Free: 1-888-961-4454 E-mail: support@researchdive.com Website: https://www.researchdive.com Blog: https://www.researchdive.com/blog/ LinkedIn: https://www.linkedin.com/company/research-dive/ Twitter: https://twitter.com/ResearchDive Facebook: https://www.facebook.com/Research-Dive-1385542314927521
